Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

BACKGROUND: PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agents at the site of disease was believed to break local immune tolerance and reduc...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Hematol Oncol
Κύριοι συγγραφείς: Yang, Yuanyuan, Zhang, Xiaolong, Lin, Fangzhen, Xiong, Mengshang, Fan, Dongmei, Yuan, Xiangfei, Lu, Yang, Song, Yuewen, Zhang, Yizi, Hao, Mu, Ye, Zhou, Zhang, Yanjun, Wang, Jianxiang, Xiong, Dongsheng
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BioMed Central 2019
Θέματα:
Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482514/
https://ncbi.nlm.nih.gov/pubmed/31023384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0723-8
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια